Spring til hovednavigation Spring til søgning Spring til hovedindhold

Surfaktantbehandling af respiratorisk distress-syndrom

Abstract

This review gives a summary of the development of a method to measure lung surfactant on gastric aspirate at birth in premature infants with the purpose to threat respiratory distress syndrome early with targeted surfactant. Machine learning was used to create the algorithm, and a point-of-care spectrometer was constructed for use in the delivery room. The sensitivity was 91% and specificity 79% in a clinical trial. The same method was used to measure surfactant in tracheal fluid in patients with COVID-19 since lung surfactant may be diminished in these patients.

Bidragets oversatte titelSurfactant therapy of respiratory distress syndrome
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind183
Udgave nummer44
ISSN0041-5782
StatusUdgivet - 1 nov. 2021

Emneord

  • COVID-19
  • Humans
  • Infant
  • Infant, Newborn
  • Pulmonary Surfactants/therapeutic use
  • Respiratory Distress Syndrome, Newborn/drug therapy
  • SARS-CoV-2
  • Surface-Active Agents/therapeutic use

Fingeraftryk

Dyk ned i forskningsemnerne om 'Surfaktantbehandling af respiratorisk distress-syndrom'. Sammen danner de et unikt fingeraftryk.

Citationsformater